In summary, our study showed a reduction of immune cell influx through blockade of E-selectin readily suppresses DOX-induced TH2 shift and fibrosis, highlighting the potential advantage of controlling DOX-induced immune cell infiltration and presenting an opportunity for supportive care in combination with DOX that could potentially improve outcomes and reduce adverse effects in BC treatment. The gene discussed is SELE; the disease is breast cancer.